These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 8880631)
1. Tissue plasminogen activator and plasminogen activator inhibitors of type 1 and type 2 in the plasma of parturient women. Uszyński M; Uszyński W; Zekanowska E; Garbacz J; Kielkowski A; Marcinkowski Z J Perinat Med; 1996; 24(4):339-45. PubMed ID: 8880631 [TBL] [Abstract][Full Text] [Related]
2. Tissue plasminogen activator and plasminogen activator inhibitors of types 1 and 2 in amniotic fluid before labour and after childbirth. Uszyński M; Uszyński W; Kiełkowski A Gynecol Obstet Invest; 1995; 39(2):93-6. PubMed ID: 7737590 [TBL] [Abstract][Full Text] [Related]
3. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium. Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y Agents Actions Suppl; 1992; 38 ( Pt 2)():320-9. PubMed ID: 1462839 [TBL] [Abstract][Full Text] [Related]
4. Placenta and myometrium--the two main sources of fibrinolytic components during pregnancy. Uszyński M; Maciejewski K; Uszyński W; Kuczyński J Gynecol Obstet Invest; 2001; 52(3):189-93. PubMed ID: 11598362 [TBL] [Abstract][Full Text] [Related]
5. Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy. Coolman M; de Groot CJ; Steegers EA; Geurts-Moespot A; Thomas CM; Steegers-Theunissen RP; Sweep FC Eur J Obstet Gynecol Reprod Biol; 2006; 128(1-2):22-8. PubMed ID: 16584829 [TBL] [Abstract][Full Text] [Related]
6. Effects of labor and delivery on fibrinolysis. Bremer HA; Brommer EJ; Wallenburg HC Eur J Obstet Gynecol Reprod Biol; 1994 Jun; 55(3):163-8. PubMed ID: 7958159 [TBL] [Abstract][Full Text] [Related]
7. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580 [TBL] [Abstract][Full Text] [Related]
8. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta. Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950 [TBL] [Abstract][Full Text] [Related]
9. Relationship of urokinase type plasminogen activator, plasminogen activator inhibitor type 1 and activated protein C in fibrinolysis of human placenta. Moniwa N Pol J Pharmacol; 1996; 48(2):215-20. PubMed ID: 9112654 [TBL] [Abstract][Full Text] [Related]
10. Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors. Nakashima A; Kobayashi T; Terao T Gynecol Obstet Invest; 1996; 42(2):95-101. PubMed ID: 8878712 [TBL] [Abstract][Full Text] [Related]
11. Enhanced PAI-1 levels from early second trimester and during labour and plasminogen activators in normal pregnancy. Koh SC; Anandakumar C; Biswas A; Fong YF Thromb Haemost; 2002 Jan; 87(1):175-6. PubMed ID: 11858184 [No Abstract] [Full Text] [Related]
12. Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease. Leiper K; Croll A; Booth NA; Moore NR; Sinclair T; Bennett B J Clin Pathol; 1994 Mar; 47(3):214-7. PubMed ID: 8163691 [TBL] [Abstract][Full Text] [Related]